Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31308 | 0.89 | NAAA (0.51) | NAAAKDM4EALOX5PIK3CDNR1H2 | |
| SCHEMBL9250191 | 0.87 | NAAA (0.54) | NAAAKDM4EALOX5PIK3CDNR1H2 | |
| SCHEMBL419534 | 0.87 | NAAA (0.54) | NAAAKDM4EALOX5PIK3CDNR1H2 | |
| SCHEMBL27992732 | 0.87 | NAAA (0.54) | NAAAKDM4EALOX5PIK3CDNR1H2 | |
| Hydrogen Sulfide SCHEMBL28268418 | 0.87 | NAAA (0.50) | NAAAKDM4EALOX5PIK3CDNR1H2 | |
| SCHEMBL14184720 | 0.87 | NAAA (0.54) | NAAAKDM4EALOX5PIK3CDNR1H2 | |
| SCHEMBL4860823 | 0.87 | NAAA (0.54) | NAAAKDM4EALOX5PIK3CDNR1H2 | |
| SCHEMBL8512828 | 0.87 | NAAA (0.54) | NAAAKDM4EALOX5PIK3CDNR1H2 | |
| SCHEMBL4573839 | 0.84 | NAAA (0.49) | NAAAKDM4EPIK3CDNR1H2MEN1 | |
| SCHEMBL8516440 | 0.82 | PIK3CD (0.54) | NAAAKDM4EALOX5PIK3CDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6458787-B1 | NOVEL PYRROLIDINE COMPOUNDS THAT ARE POTENT AND SELECTIVE INHIBITORS OF PDE4, AS WELL AS METHODS OF MAKING THE SAME, ARE DISCLOSED. USE OF THE COMPOUNDS IN THE TREATMENT OF INFLAMMATORY DISEASES AND OTHER DISEASES INVOLVING ELEVATED | ICOS CORPORATION | 2002-10-01 | — | — | US | disclosed |
| EP-1242407-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6455562-B1 | TREATMENT OF INFLAMMATORY DISEASES AND OTHER DISEASES INVOLVING ELEVATED LEVELS OF CYTOKINES, AS WELL AS CENTRAL NERVOUS SYSTEM DISORDERS | ICOS CORPORATION | 2002-09-24 | — | — | US | disclosed |
| US-20020032224-A1 | Treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system disorders | ICOS CORPORATION | 2002-03-14 | — | — | US | disclosed |
| US-6294561-B1 | ENZYME INHIBITORS FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS | ICOS CORPORATION | 2001-09-25 | — | — | US | disclosed |
| US-6258833-B1 | ENZYME INHIBITORS AND ANTIINFLAMMATORY AGENTS | ICOS CORPORATION | 2001-07-10 | — | — | US | disclosed |
| WO-2001047914-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032224-A1 | Treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system disorders | PDE4A, PDE4B, PDE4C | NAAA 1133/4885KDM4E 2796/4885ALOX5 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.